Serum glycoprotein markers in non-alcoholic steato-hepatitis and hepatocellular carcinoma
Authors:
- Prasanna RamachandranPRPrasanna Ramachandran
- Klaus Lind-PaintnerKLKlaus Lind-Paintner
Preprint
Abstract
Fatty liver disease progresses through stages of fat accumulation and inflammation to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis and eventually hepatocellular carcinoma (HCC). Currently available diagnostic tools for HCC lack sensitivity and specificity and deliver little value to patients. In this study, we investigated the use of circulating serum glycoproteins to identify a panel of potential prognostic markers that may be indicative of progression from the healthy state to NASH and further to HCC. Serum samples were processed using a standard pre-analytical sample preparation protocol and were analyzed using a novel high throughput glycoproteomics platform. We analyzed 413 glycopeptides, representing 57 abundant serum proteins and compared among the three phenotypes. Our initial dataset contained healthy, NASH, and HCC serum samples. We analyzed normalized abundance of common glycoforms and found 40 glycopeptides with statistically significant differences in abundances in NASH and HCC compared to controls. Summary level relative abundance of core-fucosylated, sialylated and branched glycans containing glycopeptides were higher in NASH and HCC as compared to controls. We replicated some of our findings in an independent set of samples of individuals with benign liver conditions and HCC, respectively. Our results may be of value in the management of liver diseases. TOC only:Keywords
This publication has 41 references indexed in Scilit:
- Quantification of Fucosylated Hemopexin and Complement Factor H in Plasma of Patients with Liver DiseaseAnalytical Chemistry, 2014
- Quantitative analysis of aberrant protein glycosylation in liver cancer plasma by AAL-enrichment and MRM mass spectrometryThe Analyst, 2013
- Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial ResultsPLOS ONE, 2013
- Alpha-l-fucosidase as a tumour marker of hepatocellular carcinomaArab Journal of Gastroenterology, 2012
- Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resectionJournal of Cancer Research and Clinical Oncology, 2010
- Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic SteatohepatitisHepatology, 2009
- Alteration of protein glycosylation in liver diseasesJournal of Hepatology, 2009
- Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2007
- Clinicopathologic and prognostic values ofapolipoprotein Dalterations in hepatocellular carcinomaInternational Journal of Cancer, 2005
- α1‐Acid glycoprotein fucosylation as a marker of carcinoma progression and prognosisCancer, 2004